Expectations trend
FY2028 · fiscal year ending 2028-09-30 · fmp
$2.27 → $2.27 · observed estimates
Anavex Life Sciences Corp. (AVXL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.11-11.90%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
2.27 → 2.27 EPS · FY ending Sep 30, 2028 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for AVXL yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advance clinical development programs to reach regulatory milestones | A primary condition in Anavex Life Sciences Corp.'s published investment case. The stated target is progress clinical trials and reach key regulatory steps. | Improving | clinical trial progress stalls or regulatory milestones missed | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-09-30 · fmp
$2.27 → $2.27 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
AVXL is a high-risk, loss-making clinical-stage biotechnology company, so its long-term thesis depends more on advancing its drug programs than on steady earnings. The thesis is marked intact, but confidence is low and recent financial strength does not establish clinical progress.
The evidence does not include valuation or market-expectation measures, so it is not possible to say whether AVXL looks cheap, fair, or expensive versus peers, or what expectations are already reflected. The two recent earnings beats are positive, but they do not show how much progress the market assumes for the clinical programs.
Near term, operating income improved to a profit in Q3 after losses in the two prior quarters, and AVXL reported two recent earnings beats. However, the evidence flags elevated risk of another earnings miss, including a recent miss against its own guidance, while the reported financial figures do not establish clinical progress. Over the multi-year view, FDA clearance of the Fragile X IND and reported study completion are milestones, but delivery against management’s broader program and capital-use priorities remains unclear.
The multi-year thesis hinges on advancing blarcamesine across its core indications and converting regulatory milestones into demonstrable clinical progress. Near term, a guidance cut would be a negative signal; weakening jobs data may also weigh on healthcare-sector sentiment, while continued strong results from sector bellwethers could support that backdrop.
The long-term thesis remains intact, but low confidence, loss-making operations, and elevated near-term execution risk make the evidence mixed. The central question is whether clinical and regulatory milestones turn into clearer program progress over the next one to three years. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Manage cash burn to improve cash from operations toward -$5.9M |
| A supporting condition in Anavex Life Sciences Corp.'s published investment case. The stated target is cash from operations >= -$5.9M. |
| Under Pressure |
| cash burn worsens beyond -$5.9M |
Cash from operations: $-13.536M FY2026-Q3; GAAP. Published target: cash from operations >= -$5.9M. The stored target says 2025-Q2; this source reports FY2026-Q3. Fiscal/calendar alignment needs review. Aug 28, 2026-13,536,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating losses toward -$6.8M per quarter | A primary condition in Anavex Life Sciences Corp.'s published investment case. The stated target is operating loss <= -$6.8M per quarter. | Broken | operating loss worsens beyond -$6.8M per quarter | Operating income: $6.737M FY2026-Q3; GAAP. Published target: operating loss <= -$6.8M per quarter. The stored target says 2026-Q1; this source reports FY2026-Q3. Fiscal/calendar alignment needs review. Aug 28, 20266,737,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stabilize leadership and governance after executive changes | A supporting condition in Anavex Life Sciences Corp.'s published investment case. The stated target is board and executive team stabilized with no major departures. | Under Pressure | further major executive departures or governance issues | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 1 supplied quarters. Management reported: ““Dr. Kellmeyer has provided steady leadership and a clear vision during an important period for Anavex, sharpening the focus of our clinical programs and advancing our engagement with the FDA,” said Peter Donhauser, D.O., member of the Board of Directors.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.35B → $0.35B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-01 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-02 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-03 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-04 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-05 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-06 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-07 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-08 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-09 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-10 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-11 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-12 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-13 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-14 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-15 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-16 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-17 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-18 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-19 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-20 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-21 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-22 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-23 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-24 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-25 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-26 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-27 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-28 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-29 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-30 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-10-31 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-11-01 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-11-02 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-11-03 | $2.27 | $348,569,000 | 1 / 1 |
| 2026-11-04 | $2.27 | $348,569,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 24, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.